Patient reported outcomes in melanoma

Rebecca Wiltshire is a DPhil student and nurse based in the Department of Oncology and Nuffield Department of Population Health. Her background is Oncology and Haematology nursing, particularly in early phase clinical trials.

Checkpoint-inhibitor immunotherapy is an important new treatment option for many clinicians and their patients, and one of the main treatments for melanoma. These reagents are able to cure some patients who would historically have had relatively poor prognosis. For others, the benefits are more limited and given the drugs come with significant risk of major side effects. Therefore understanding in more detail how checkpoint inhibitor immunotherapies affect patients’ quality of life (both in terms of side effects and how the practicalities of treatment affect patients) is crucial in terms of systematic integration into standard of care.

Patient Reported Outcome Measures (PROM) are increasingly used in cancer care, particularly as the focus shifts from survival to living with the disease – and living with the side effects of treatment. Becky’s work connects Immuno-oncology and Population Health in developing PROM and patient experience questionnaire for those undergoing checkpoint-inhibitor immunotherapy to give healthcare professionals a better understanding of the patients’ quality of life, both during and after treatment. Cancer Research UK calls for research protocols to be developed with a view to gaining better insight and understanding of patient experience and quality of life. The development of a PROM for patients receiving checkpoint inhibitor immunotherapies will facilitate this.

“The patient experience questionnaire will give us a better understanding of the patients’ perspective regarding their treatment. It will allow us to develop and design clinical services to better meet their [melanoma patients’] needs.”

In Oxford Becky collaborates with Michele Peters (NDPH) and Mark Middleton (Oncology), she is funded by the Department of Oncology.

Find out more about our research below

Cancer immunologist Lieping Chen joins Ludwig Oxford as a Visiting Professor

Oxford is delighted to welcome this acclaimed scientist to the Branch and the Ludwig Oxford community.

Using Herpesvirus to fight cancer

The Seymour lab at the Department of Oncology, University of Oxford, has published a new paper investigating the use of oncolytic herpes virus-1 as a vector to augment immunotherapy in cancer

T-cell landscape mapping identifies new targets for pancreatic cancer immunotherapy

Through analysis of T-cell populations, Oxford pancreatic researchers identify novel therapeutic opportunities in pancreatic cancer patients
Doctor looking at skin

Higher testosterone levels in men linked to greater melanoma risk

New research from Dr Eleanor Watts at the Nuffield Department of Population Health has found this association for the first time

DeLIVER clinical research study underway as recruitment opens

The DELPHI project, one of three clinical studies within the DeLIVER programme for early detection of liver cancer, has started recruiting patients.

Prof Andi Roy receives new award for immune-cell research

Co-funded by Cancer Research UK and Children with Cancer UK, Andi is one of 5 to receive £1 million each to investigate children’s and young people’s cancers.
An animated drawing of a syringe releasing contents that attacks cancer cells

Improving immunotherapy through epigenetics

Professor Yang Shi’s group uses combination therapy to eradicate tumours that previously responded poorly to immunotherapy
Christina Ye

Christina Ye awarded CRUK pre-doctoral fellowship

Christina Ye has been awarded CRUK pre-doctoral fellowship, she tells us about her upcoming project into T cell trafficking between the blood and skin when patients undergo checkpoint immunotherapy

New melanoma drug a step closer to the clinic

Clinical trials into the use of Tebentafusp for metastatic uveal melanoma have been conducted by the University of Oxford and Immunocore. The positive results of the most recent trial mean this drug could now be used in future treatment.